South Korea Diabetes Drug Market Overview, 2030

South Korea’s diabetes drug market is experiencing significant growth due to rising disease prevalence, expanding elderly populations, and increasing adoption of advanced therapies. According to national data, the average annual diabetes-related healthcare expenditure per person in South Korea is approximately USD 2312 with total national expenditures exceeding USD 11.63 billion annually. This includes both direct medical costs, which account for nearly 72% approx, and indirect costs such as lost productivity. South Korea has emerged as a center for pharmaceutical innovation, with domestic companies such as Hanmi, Daewoong, and Celltrion partnering with global giants like Novo Nordisk and Eli Lilly to co-develop and distribute biosimilar insulins and novel oral combination drugs. In addition, digital health is rapidly being integrated into diabetes care smart pens, continuous glucose monitors (CGMs), and AI-powered insulin dosing systems and telemedicine platforms are increasingly used by over 30% of patients, improving compliance and disease management. Regulatory authorities, particularly the Ministry of Food and Drug Safety (MFDS), have streamlined clinical approval processes and expanded the reimbursement framework to accommodate newer therapies and digital devices. Demand is further driven by South Korea's highly urbanized healthcare infrastructure, with widespread access to hospitals, specialized diabetes clinics, and advanced diagnostic tools. Enhanced screening programs by the Ministry of Health and Welfare have led to earlier diagnoses, increasing the number of patients entering treatment at less advanced disease stages and thereby expanding drug consumption over a longer time horizon. Moreover, the government has launched healthcare policy reforms for 2024–2028, focusing on balancing cost containment with support for medical innovation, which includes broader coverage for digital solutions and enhanced support for chronic disease care.

According to the research report ""South Korea Diabetes Drug Market Overview, 2030,"" published by Bonafide Research, the South Korea Diabetes Drug market was valued at more than USD 1.14 Billion in 2024. The The South Korea diabetes drugs market is moving towards personalized therapy, new drug delivery technologies, and digital health integration. The development of long-acting insulins, ultra-rapid formulations, and AI-driven treatment programs is anticipated to improve patient outcomes. Smart insulin pens, continuous glucose monitoring (CGM) devices, and digital treatments will help to increase adherence and self-management. Research into gene-based and regenerative therapies may lead to curative treatments that go beyond glucose control, ushering in a paradigm shift in diabetes care. With continued improvements, the future of diabetic medications in South Korea will center on precision medicine, increased patient convenience, and comprehensive disease management. Generic medicine competition hinders the growth of the South Korean diabetes drugs market by producing price erosion and restricting pharmaceutical innovation. COFEPRIS indicates that generics account for 84% of the market, indicating a strong preference for low-cost alternatives over branded pharmaceuticals. While generics increase affordability, they decrease revenue for pharmaceutical businesses. This prevents companies from investing in innovative diabetes treatments. Technological advancements and evolving treatment preferences are also key contributors to market growth. There is a growing shift from traditional oral anti-diabetics to novel drug classes like SGLT-2 inhibitors, GLP-1 receptor agonists, and dual therapies such as tirzepatide, as patients and healthcare providers prioritize better efficacy, fewer side effects, and cardiovascular benefits.

Insulin remains a foundational therapy, especially for individuals with type 1 diabetes and for those with long-standing type 2 diabetes requiring intensified glycemic control. South Korea’s National Health Insurance Service (NHIS) supports the widespread use of insulin, and advancements in insulin delivery systems such as insulin pens and continuous glucose monitors have improved patient compliance. The use of long-acting basal insulins such as insulin glargine and insulin degludec has gained traction due to their convenience and lower risk of hypoglycemia. GLP-1 receptor agonists are witnessing increasing demand in South Korea due to their dual benefit of glycemic control and weight loss. The growing incidence of obesity-related type 2 diabetes in urban areas has driven interest in GLP-1 drugs like liraglutide and semaglutide. South Korea’s health authorities have also begun approving once-weekly GLP-1 therapies, reflecting a preference for convenient regimens with cardiovascular benefits. DPP-4 inhibitors enjoy strong market penetration in South Korea, largely due to their oral administration, low side effect profile, and favorable reimbursement status. Drugs like sitagliptin and linagliptin are especially preferred among elderly patients who may be sensitive to hypoglycemia or have renal complications. South Korea ranks among the highest consumers of DPP-4 inhibitors globally, and their popularity continues due to physician comfort and wide patient suitability. SGLT2 inhibitors are also gaining momentum, particularly for their cardiovascular and renal protection effects. Medications like empagliflozin and dapagliflozin are increasingly used in patients with type 2 diabetes and comorbidities, and South Korean guidelines have recently emphasized their use in heart failure and chronic kidney disease patients. The ‘Others’ category, including metformin, sulfonylureas, and combination therapies, still holds a major share of the market. Metformin remains the first-line treatment due to its affordability, efficacy, and long-term safety profile.

The demand for Type-2 diabetes drugs is particularly high for oral antidiabetic medications such as metformin, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. South Korea has developed its own DPP-4 inhibitors, such as gemigliptin and evogliptin, reflecting strong local pharmaceutical innovation. The market also shows increasing preference for combination therapies and newer classes like GLP-1 agonists due to their cardiovascular benefits and weight loss advantages. Reimbursement policies under South Korea’s National Health Insurance have supported wide access to these therapies, covering around 70–80% of the treatment cost. Furthermore, adherence among elderly patients is high, especially with fixed-dose combinations that simplify regimens. In contrast, Type-1 diabetes accounts for a much smaller proportion less than 4% of total diabetic cases but poses a unique and complex treatment challenge. Patients with Type-1 diabetes depend heavily on insulin therapy, particularly long-acting and ultra-rapid analogues, along with advanced technologies such as continuous glucose monitors (CGMs) and insulin pumps. However, financial barriers persist, as insurance coverage is more limited for insulin pumps than for CGMs, which are partly reimbursed. Out-of-pocket expenses for CGM sensors and insulin pens remain a burden for many patients, despite growing demand for smart, integrated solutions. Korean innovations like the EOPatch insulin pump are emerging but face adoption challenges due to lack of coverage.

Oral drugs such as metformin, DPP-4 inhibitors (notably linagliptin and sitagliptin), and SGLT2 inhibitors (like empagliflozin) are favored for their ease of use, cost-effectiveness, and strong patient adherence. The Korean Diabetes Association promotes early and aggressive management of type 2 diabetes with OADs, especially among the aging population, which significantly contributes to the rising demand. As of 2023, over 5 million adults in South Korea are estimated to have diabetes, with nearly half unaware of their condition, further intensifying the market need for convenient and widely accessible oral therapies. Subcutaneous administration, which includes insulin and GLP-1 receptor agonists, is more prevalent among patients with type 1 diabetes and those with advanced type 2 diabetes where glycemic control is no longer achievable through oral drugs alone. Insulin therapy, while well-established, faces adherence challenges due to injection-related discomfort and stigma. However, innovations such as long-acting basal insulins (e.g., insulin glargine) and insulin pens are making treatment more tolerable. GLP-1 receptor agonists, such as liraglutide and dulaglutide, have gained momentum due to their dual benefit in weight loss and cardiovascular risk reduction, crucial for South Korea’s diabetic population with rising obesity rates. The subcutaneous segment is growing steadily, especially among younger urban populations looking for modern, multifunctional treatment options. Intravenous administration is reserved for acute and hospital-based care settings, such as managing hyperglycemic crises, diabetic ketoacidosis, or perioperative glucose control. This segment is smaller in market size but critical in terms of clinical need and hospital procurement. The demand for intravenous insulin is concentrated in tertiary hospitals and specialized diabetes centers, where complex cases are treated. South Korea’s strong hospital infrastructure and high standard of inpatient care contribute to the steady utilization of IV routes, albeit limited to acute care.

Hospital pharmacies are significant in South Korea due to the country’s well-developed and highly centralized healthcare system, where large hospitals and university medical centers handle most chronic disease management, including diabetes. These pharmacies dispense a wide range of medications, especially for patients with complex or advanced diabetes requiring insulin therapy or GLP-1 receptor agonists. Hospital pharmacies are also preferred for initiating therapy under medical supervision, particularly for newly diagnosed Type 1 or severe Type 2 diabetic patients. Retail pharmacies serve as another vital distribution channel and are particularly important for ongoing maintenance therapies, especially for patients managing Type 2 diabetes with oral medications like metformin, DPP-4 inhibitors, or SGLT2 inhibitors. These community-based pharmacies are widespread in urban and semi-urban regions, making them more accessible for regular prescription refills. South Korea’s National Health Insurance Service (NHIS) promotes medication adherence by reimbursing a broad range of diabetes medications, encouraging patients to obtain their prescriptions regularly. Additionally, the government has supported programs that allow retail pharmacists to offer basic counseling on lifestyle, diet, and medication management, further enhancing their role in chronic disease care. Online pharmacies in South Korea are still in a developing phase due to strict regulations on the sale of prescription drugs over the internet. However, there is growing interest in digital health platforms, especially following the COVID-19 pandemic, which led to a temporary relaxation of telemedicine and e-pharmacy rules. Diabetic patients, particularly those in remote areas or with mobility issues, increasingly rely on online channels for over-the-counter (OTC) products like glucose monitors and dietary supplements, and some prescription refills through authorized platforms linked to hospitals or clinics.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Diabetic Drug Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Insulin
• GLP-1 Receptor Agonists
• DPP-4 Inhibitors
• SGLT2 Inhibitors
• Others (metformin, sulfonylureas, and combination therapies)

By Diabetes
• Type-1
• Type-2

By Route of Administration
• Oral
• Subcutaneous
• Intravenous

By Distribution Channel
• Hospital Pharmacies
• Retail pharmacies
• Online Pharmacies Show more